PRNB Description — Principia Biopharma Inc

Principia Biopharma is a late-stage biopharmaceutical company focused on developing therapies for immune-related diseases. Co.'s proprietary Tailored Covalency® platform enables Co. to design and develop reversible covalent and irreversible covalent, small molecule inhibitors with potencies and selectivities. Co.'s clinical pipeline includes rilzabrutinib, PRN473 Topical, and PRN2246/SAR442168. Co.'s main candidate, rilzabrutinib, a wholly owned Bruton Tyrosine Kinase inhibitor, is in a Phase 3 trial for the treatment of pemphigus (pemphigus vulgaris and pemphigus foliaceus), and in a Phase 1/2 trial for the treatment of Immune Thrombocytopenia.

Company Name: 
Principia Biopharma Inc
Drugs & Pharmaceuticals
Number of ETFs Holding PRNB: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   PRNB Weight   PRNB Amount 
 VTI   0.01%   $38,914,496         
 IWM   0.07%   $24,142,156         
 IBB   0.26%   $16,570,587         
 VXF   0.03%   $15,436,532         
 IWO   0.13%   $8,775,942         
 VHT   0.03%   $3,347,889         
 IWC   0.44%   $2,400,316         
 FYX   0.58%   $1,925,475         
 FPX   0.16%   $1,584,773         
 VTWO   0.08%   $1,206,130         
List of all 28 ETFs holding PRNB »
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
85th percentile
(ranked higher than approx. 85% of all stocks covered)
Based on data provided by Zacks Investment Research via

ETFs Holding PRNB | Principia Biopharma Inc | ETF Channel |

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.